Brought to you by 
BMS partners Sprycel and Ixempra with Otsuka
26 Aug 2015
Executive Summary
In a ten-year agreement that takes effect in 2010, Bristol-Myers Squibb has partnered its leukemia treatment Sprycel (dasatinib) and advanced breast cancer drug Ixempra (ixabepilone) with Otsuka Pharmaceutical in the US, Europe, and Japan. The deal includes present and future indications of the products.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS partners Sprycel and Ixempra with Otsuka
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice